Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 21Glioblastoma 5Endometrial Neoplasms 5Breast Neoplasms 5Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Leukoplakia, Oral 3Insulin Resistance 3Ovarian Neoplasms 2Metabolic Syndrome 2Metabolic Diseases 2Medulloblastoma 2Infertility 2Erythroplasia 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Adenocarcinoma Of Esophagus 2Weight Loss 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Thyroid Diseases 1TP53 Y220C Mutation 1Smoldering Multiple Myeloma 1Sarcoma 1Rectal Neoplasms 1Prostate Cancer Recurrent 1Prediabetic State 1Posterior Fossa Ependymal Tumor 1Pleural Effusion, Malignant 1

Interventions

Lenalidomide 7Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Leflunomide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Metformin × 1 year × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡